Periprocedural Bridging Management of Anticoagulation

Atrial Fibrillation Friday, July 27th, 2012

Circ.ahajournals.org: 7/24/12.

More than 2.5 million Americans are chronically anticoagulated for indications including venous thromboembolism (VTE), mechanical heart valve(s), or atrial fibrillation (AF).1 Each year, ≈10% of these patients require temporary interruption of anticoagulation for an invasive procedure. Defining the most appropriate management strategy for these patients requires an assessment of the periprocedural risk of thromboembolism and major hemorrhage. Bridging therapy is a recent term used to describe the application of a parenteral, short-acting anticoagulant during the interruption of warfarin. Read More

National Minority Quality Forum Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2011 National Minority Quality Forum, Inc. All Rights Reserved.